150 related articles for article (PubMed ID: 38443329)
41. Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication.
Tanabe H; Yoshino K; Ando K; Nomura Y; Ohta K; Satoh K; Ichiishi E; Ishizuka A; Otake T; Kohgo Y; Fujiya M; Okumura T
Ann Clin Microbiol Antimicrob; 2018 Jun; 17(1):29. PubMed ID: 29950163
[TBL] [Abstract][Full Text] [Related]
42. Sequential versus standard triple first-line therapy for Helicobacter pylori eradication.
Nyssen OP; McNicholl AG; Megraud F; Savarino V; Oderda G; Fallone CA; Fischbach L; Bazzoli F; Gisbert JP
Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD009034. PubMed ID: 27351542
[TBL] [Abstract][Full Text] [Related]
43. Bismuth-Containing Quadruple Therapy for Helicobacter pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days.
Ding YM; Duan M; Han ZX; Song XH; Zhang FL; Wang Z; Ning Z; Zeng SY; Kong QZ; Zhang WL; Liu J; Wan M; Lin MJ; Lin BS; Nan XP; Wang H; Li YY; Zuo XL; Li YQ
Dig Dis Sci; 2024 May; ():. PubMed ID: 38700630
[TBL] [Abstract][Full Text] [Related]
44. Eradication rate and safety of a "simplified rescue therapy": 14-day vonoprazan and amoxicillin dual regimen as rescue therapy on treatment of Helicobacter pylori infection previously failed in eradication: A real-world, retrospective clinical study in China.
Gao W; Teng G; Wang C; Xu Y; Li Y; Cheng H
Helicobacter; 2022 Oct; 27(5):e12918. PubMed ID: 35877765
[TBL] [Abstract][Full Text] [Related]
45. High-dose dual therapy versus bismuth-containing quadruple therapy for the treatment of
Zhang C; Zhang J; Cheng YJ
Saudi J Gastroenterol; 2023; 29(2):88-94. PubMed ID: 36960527
[TBL] [Abstract][Full Text] [Related]
46. Efficacy of tegoprazan-based bismuth quadruple therapy compared with bismuth quadruple therapy for Helicobacter pylori infection: A randomized, double-blind, active-controlled study.
Kim JS; Ko W; Chung JW; Kim TH
Helicobacter; 2023 Jun; 28(3):e12977. PubMed ID: 37083222
[TBL] [Abstract][Full Text] [Related]
47. Randomized Clinical Trial: Esomeprazole, Bismuth, Levofloxacin, and Amoxicillin or Cefuroxime as First-Line Eradication Regimens for Helicobacter pylori Infection.
Fu W; Song Z; Zhou L; Xue Y; Ding Y; Suo B; Tian X; Wang L
Dig Dis Sci; 2017 Jun; 62(6):1580-1589. PubMed ID: 28391418
[TBL] [Abstract][Full Text] [Related]
48. The cure rate of 10-day bismuth-containing quadruple therapy for Helicobacter pylori eradication is equivalent to 14-day: a systematic review and meta-analysis.
Ding YM; Li YY; Liu J; Wang J; Wan M; Lin MJ; Lin BS; Zhang WL; Kong QZ; Wang ST; Mu YJ; Duan M; Han ZX; Zuo XL; Li YQ
Clin Exp Med; 2023 Aug; 23(4):1033-1043. PubMed ID: 36538198
[TBL] [Abstract][Full Text] [Related]
49. High-Dose Dual Therapy Versus Bismuth-Containing Quadruple Therapy for the Treatment of Helicobacter pylori Infection: A Systematic Review with Meta-Analysis.
Yin Z; Li J; Huang W; Lei X; Xu D; Xu G; Li H; Zhang J
Turk J Gastroenterol; 2022 Jun; 33(6):454-462. PubMed ID: 35786612
[TBL] [Abstract][Full Text] [Related]
50. Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori: A multicenter retrospective study in clinical practice.
Shichijo S; Hirata Y; Niikura R; Hayakawa Y; Yamada A; Mochizuki S; Matsuo K; Isomura Y; Seto M; Suzuki N; Suzuki H; Yamamoto S; Sugimoto T; Omae T; Okamoto M; Watabe H; Togo G; Takano N; Fukui K; Ito Y; Koike K
J Dig Dis; 2016 Oct; 17(10):670-675. PubMed ID: 27534444
[TBL] [Abstract][Full Text] [Related]
51. [Quadruple regimens using domestically manufactured drugs in gastritis and duodenal ulcer patients for Helicobacter pylori eradication: a perspective, multicenter, randomized controlled trial].
Gao W; Hu F; Cheng H; Wang H; Yang Y; Liang H; Zhang S; Meng F; Cui M; Wei H; Sheng J; An HJ; Jiang B; Chen Y; Li Y; Zuo X; Gong J; Zhao P; Dong L; Wang B; Jiang K; Zhang G; Li J; Zhao Y; Gao H; Yang L
Zhonghua Yi Xue Za Zhi; 2016 Jan; 96(4):260-4. PubMed ID: 26879784
[TBL] [Abstract][Full Text] [Related]
52. Randomized clinical trial: 7-day vonoprazan-based versus 14-day omeprazole-based triple therapy for Helicobacter pylori.
Bunchorntavakul C; Buranathawornsom A
J Gastroenterol Hepatol; 2021 Dec; 36(12):3308-3313. PubMed ID: 34622504
[TBL] [Abstract][Full Text] [Related]
53. Comparative study: Vonoprazan and proton pump inhibitors in
Sakurai K; Suda H; Ido Y; Takeichi T; Okuda A; Hasuda K; Hattori M
World J Gastroenterol; 2017 Jan; 23(4):668-675. PubMed ID: 28216974
[TBL] [Abstract][Full Text] [Related]
54. High Effective of 14-Day High-Dose PPI- Bismuth-Containing Quadruple Therapy with Probiotics Supplement for Helicobacter Pylori Eradication: A Double Blinded-Randomized Placebo-Controlled Study.
Poonyam P; Chotivitayatarakorn P; Vilaichone RK
Asian Pac J Cancer Prev; 2019 Sep; 20(9):2859-2864. PubMed ID: 31554388
[TBL] [Abstract][Full Text] [Related]
55. Clinical impact of vonoprazan-based dual therapy with amoxicillin for H. pylori infection in a treatment-naïve cohort of junior high school students in Japan.
Gotoda T; Kusano C; Suzuki S; Horii T; Ichijima R; Ikehara H
J Gastroenterol; 2020 Oct; 55(10):969-976. PubMed ID: 32666199
[TBL] [Abstract][Full Text] [Related]
56. Fourteen- vs seven-day bismuth-based quadruple therapy for second-line Helicobacter pylori eradication.
Hwang JJ; Lee DH; Lee AR; Yoon H; Shin CM; Park YS; Kim N
World J Gastroenterol; 2015 Jul; 21(26):8132-9. PubMed ID: 26185386
[TBL] [Abstract][Full Text] [Related]
57. European Registry on Helicobacter pylori management: Single-capsule bismuth quadruple therapy is effective in real-world clinical practice.
Nyssen OP; Perez-Aisa A; Castro-Fernandez M; Pellicano R; Huguet JM; Rodrigo L; Ortuñ J; O ; Gomez-Rodriguez BJ; Pinto RM; Areia M; Perona M; Nuñez O; Romano M; Gravina AG; Pozzati L; Fernandez-Bermejo M; Venerito M; Malfertheiner P; Fernanadez-Salazar L; Gasbarrini A; Vaira D; Puig I; Megraud F; O'Morain C; Gisbert JP;
United European Gastroenterol J; 2021 Feb; 9(1):38-46. PubMed ID: 33176617
[TBL] [Abstract][Full Text] [Related]
58. Comparative study of allicin-containing quadruple therapy vs. bismuth-containing quadruple therapy for the treatment of Helicobacter pylori infection: a prospective randomized study.
Li H; Xia XJ; Zhang LF; Chi JS; Liu P; Wu H; Xie XR; Tian DL; Kun KX; Gong RJ; Liu XM; Xu CX
Eur J Gastroenterol Hepatol; 2021 Feb; 32(2):194-200. PubMed ID: 32804837
[TBL] [Abstract][Full Text] [Related]
59. Efficacies of different proton pump inhibitor-based 14-day bismuth-furazolidone quadruple regimens for the initial eradication of Helicobacter pylori in the southeast coastal region of China: an open-label, randomized clinical trial.
Chen L; He J; Wang L; Ge Q; Chu H; Chen Y; Chen X; Long Y; Deng Y; He H; Li A; Chen S
Clin Exp Med; 2018 Nov; 18(4):569-576. PubMed ID: 29876770
[TBL] [Abstract][Full Text] [Related]
60. Vonoprazan improves the efficacy of Helicobacter pylori eradication therapy with a regimen consisting of clarithromycin and metronidazole in patients allergic to penicillin.
Ono S; Kato M; Nakagawa S; Mabe K; Sakamoto N
Helicobacter; 2017 Jun; 22(3):. PubMed ID: 28098408
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
